Abstract:Lysine-specific demethylase 4 A (KDM4A, also named JMJD2A, KIA0677, or JHDM3A) is a demethylase that can remove methyl groups from histones H3K9me2/3, H3K36me2/3, and H1.4K26me2/me3. Accumulating evidence suggests that KDM4A is not only involved in body homeostasis (such as cell proliferation, migration and differentiation, and tissue development) but also associated with multiple human diseases, especially cancers. Recently, an increasing number of studies have shown that pharmacological inhibition of KDM4A significantly attenuates tumor progression in vitro and in vivo in a range of solid tumors and acute myeloid leukemia. Although there are several reviews on the roles of the KDM4 subfamily in cancer development and therapy, all of them only briefly introduce the roles of KDM4A in cancer without systematically summarizing the specific mechanisms of KDM4A in various physiological and pathological processes, especially in tumorigenesis, which greatly limits advances in the understanding of the roles of KDM4A in a variety of cancers, discovering targeted selective KDM4A inhibitors, and exploring the adaptive profiles of KDM4A antagonists. Herein, we present the structure and functions of KDM4A, simply outline the functions of KDM4A in homeostasis and non-cancer diseases, summarize the role of KDM4A and its distinct target genes in the development of a variety of cancers, systematically classify KDM4A inhibitors, summarize the difficulties encountered in the research of KDM4A and the discovery of related drugs, and provide the corresponding solutions, which would contribute to understanding the recent research trends on KDM4A and advancing the progression of KDM4A as a drug target in cancer therapy.

Crystal structures of two inhibitors in complex with histone lysine demethylase 4D (KDM4D) provide new insights for rational drug design

Discovery of Pyrazolo[1,5-A]pyrimidine-3-carbonitrile Derivatives As a New Class of Histone Lysine Demethylase 4D (KDM4D) Inhibitors.

Discovery of a Potent and Selective Inhibitor of Histone Lysine Demethylase KDM4D

Design, Synthesis and Biological Evaluation of 4,6-Diarylquinoxaline-based KDM4D Inhibitors

Structural Simulation and Selective Inhibitor Discovery Study for Histone Demethylases KDM4E/6B from a Computational Perspective

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Targeting N‐methyl‐lysine histone demethylase KDM4 in cancer: natural products inhibitors as a driving force for epigenetic drug discovery

Identification of the KDM2/7 Histone Lysine Demethylase Subfamily Inhibitor and Its Antiproliferative Activity.

Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present)

Small Molecule KDM4s Inhibitors As Anti-Cancer Agents

Recent Advances with KDM4 Inhibitors and Potential Applications.

Structure-based discovery of selective histone deacetylase (HDAC) 3 and 4 inhibitors

Targeting Epigenetic Reader and Eraser: Rational Design, Synthesis and in Vitro Evaluation of Dimethylisoxazoles Derivatives As BRD4/HDAC Dual Inhibitors

Structure-Based Identification of Novel Histone Deacetylase 4 (HDAC4) Inhibitors

Discovery of KDM5A Inhibitors: Homology Modeling, Virtual Screening and Structure-Activity Relationship Analysis.

Development of the Triazole-Fused Pyrimidine Derivatives As Highly Potent and Reversible Inhibitors of Histone Lysine Specific Demethylase 1 (LSD1/KDM1A)

The emerging roles of lysine-specific demethylase 4A in cancer: Implications in tumorigenesis and therapeutic opportunities

Discovery of a Series of Small Molecules As Potent Histone Deacetylase Inhibitors

Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors.

Fragment-based Drug Discovery of 2-Thiazolidinones As Inhibitors of the Histone Reader BRD4 Bromodomain.

KDM4B: A promising oncology therapeutic target